GSK Wins Japanese Approval For Cervarix As First Cervical Cancer Vaccine In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - GlaxoSmithKline K.K., the fully-owned Japanese subsidiary of GlaxoSmithKline, has won Japan's Ministry of Health, Labor and Welfare approval for cervical cancer vaccine Cervarix, the first cervical cancer vaccine to be marketed in Japan, the company announced Oct. 16